Gastroesophageal Junction Cancer clinical trials at UCSD
2 in progress, 1 open to eligible people
Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
open to eligible people ages 18 years and up
This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the RP2D of MCLA-158 single agent in patients with mCRC. The dose escalation part has been completed and the RP2D will be further evaluated in an expansion part of the study. Cohorts of selected solid tumor indications for which there is evidence of EGFR dependency and potential sensitivity to EGFR inhibition will be evaluated including head and neck cancer. The study will further assess the safety, tolerability, PK, PD, immunogenicity, and anti-tumor activity of MCLA-158.
La Jolla, California and other locations
XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
Sorry, in progress, not accepting new patients
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb23104 monotherapy and combination therapy with ipilimumab in subjects with selected advanced solid tumors.
San Diego, California and other locations
Our lead scientists for Gastroesophageal Junction Cancer research studies include Shumei Kato, MD.
Last updated: